Imaging After GliaSite Brachytherapy: Prognostic MRI Indicators of Disease Control and Recurrence
| Autor: | Geoffrey Yoon, Timothy A. Chan, NA Detorie, Lawrence Kleinberg, Alessandro Olivi, John D. Weingart, Michele Parisi |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Brachytherapy medicine Humans Radiology Nuclear Medicine and imaging Prospective cohort study Pseudoprogression Survival analysis Aged Radiation medicine.diagnostic_test Brain Neoplasms business.industry Magnetic resonance imaging Middle Aged Prognosis Combined Modality Therapy Magnetic Resonance Imaging Survival Analysis Hyperintensity Radiation therapy Oncology Concomitant Disease Progression Female Radiology Neoplasm Recurrence Local Glioblastoma business |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 75:1385-1391 |
| ISSN: | 0360-3016 |
| Popis: | Purpose: In this study, we analyzed the magnetic resonance imaging (MRI) changes in patients after GliaSite treatment and characterized the prognostic MRI indicators in these patients. Methods and Materials: A total of 25 patients with recurrent glioblastoma multiforme were treated with the GliaSite Radiation Therapy System. Patients at the Johns Hopkins Hospital with recurrent glioblastoma multiforme underwent surgical resection followed by GliaSite balloon implantation. Available MRI scans for 20 patients were obtained throughout the post-GliaSite treatment course. These were reviewed and analyzed for prognostic significance. Results: After GliaSite treatment, all patients developed some degree of T{sub 1}-weighted contrast and T{sub 2}-weighted hyperintensity around the resection cavity. The development of enhancement on T{sub 1}-weighted contrast-enhanced imaging and the size of these lesions, in the absence of increasing T{sub 2}-weighted hyperintensity, before clinical progression was not associated with decreased survival. Patients with T{sub 1}-weighted enhancement >1 cm had a median survival of 13.6 months and those with T{sub 1}-weighted lesions |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|